The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
SOLTI NeoPARP: A phase II, randomized study of two schedules of iniparib plus paclitaxel and paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer (TNBC).
Antonio Llombart
No relevant relationships to disclose
Ana Lluch
No relevant relationships to disclose
Cristian Villanueva
No relevant relationships to disclose
Suzette Delaloge
No relevant relationships to disclose
Serafin Morales
No relevant relationships to disclose
Judith Balmaña
No relevant relationships to disclose
Kepa Amillano
No relevant relationships to disclose
Herve R. Bonnefoi
Honoraria - Sanofi
Ana Maria Casas
No relevant relationships to disclose
Luis Manso
No relevant relationships to disclose
Henri Hubert Roche
No relevant relationships to disclose
Santiago Gonzalez-Santiago
No relevant relationships to disclose
Joaquin Gavila
No relevant relationships to disclose
Pedro Sánchez-Rovira
No relevant relationships to disclose
Serena Di Cosimo
No relevant relationships to disclose
Eric Charpentier
Employment or Leadership Position - Sanofi
Ignacio Garcia-Ribas
Employment or Leadership Position - Sanofi
Stock Ownership - Sanofi
Frederique Madeleine Penault-Llorca
No relevant relationships to disclose
Claudia Aura
No relevant relationships to disclose
José Baselga
No relevant relationships to disclose